



August 16, 2019

Company Anicom Holdings, Inc.  
Representative Director Nobuaki Komori

(Securities Code: 8715 TSE 1<sup>st</sup> section)

Inquiries to Tatsuhiko Kamei  
Managing Executive Officer

### **Notice of the status of our activities, July 2019**

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.


Notice of the status of our activities, 2019 (From April 1, 2019 to March 31, 2020)

	April	May	June	July	August	September
Net premiums written (previous year)	<b>3,062</b> JPYmn (2,707 JPYmn)	<b>3,274</b> JPYmn (2,890 JPYmn)	<b>3,175</b> JPYmn (2,777 JPYmn)	<b>3,108</b> JPYmn (2,737 JPYmn)	JPYmn (2,790 JPYmn)	JPYmn (2,792 JPYmn)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	<b>4,725</b> (-)	<b>6,580</b> (-)	<b>6,455</b> (-)	<b>6,601</b> (-)	(-)	(-)
No. of samples for genetic testing (previous year)	<b>9,088</b> (-)	<b>10,857</b> (-)	<b>11,463</b> (-)	<b>13,234</b> (-)	(-)	(-)


	October	November	December	January	February	March
Net premiums written (previous year)	JPYmn (2,854 JPYmn)	JPYmn (2,780 JPYmn)	JPYmn (2,991 JPYmn)	JPYmn (3,100 JPYmn)	JPYmn (2,954 JPYmn)	JPYmn (3,158 JPYmn)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	(-)	(-)	(857)	(5,256)	(4,926)	(5,146)
No. of samples for genetic testing (previous year)	(-)	(-)	(-)	(517)	(2,014)	(5,211)

(Reference) "Notice of the status of our activities" will be disclosed in the middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December and March.

### Net premiums written




### No. of applicants of Doubutsu Kenkatsu (gut microbiota testing)



\*Started in December 2018

### No. of samples for genetic testing



\*Started full-scale development in January 2019